Land: Sverige
Språk: svenska
Källa: Läkemedelsverket (Medical Products Agency)
venlafaxinhydroklorid
Upjohn EESV
N06AX16
venlafaxine hydrochloride
150 mg
Depotkapsel, hård
propylenglykol Hjälpämne; venlafaxinhydroklorid 169,7 mg Aktiv substans
Apotek
Receptbelagt
Venlafaxin
Förpacknings: Blister, 7 kapslar; Blister, 10 kapslar; Blister, 15 kapslar; Blister, 28 kapslar; Blister, 30 kapslar; Blister, 56 kapslar; Blister, 60 kapslar; Blister, 98 kapslar; Blister, 14 x 1 kapslar (endos); Blister, 28 x 1 kapslar (endos); Blister, 84 x 1 kapslar (endos); Blister, 100 x 1 kapslar (endos); Burk, 14 kapslar; Burk, 20 kapslar; Burk, 50 kapslar; Burk, 100 kapslar; Burk, 1000 kapslar (sjukhusförpackning); Burk, 500 kapslar (sjukhusförpackning); Blister, 14 kapslar; Blister, 20 kapslar; Blister, 50 kapslar; Blister, 100 kapslar; Blister, 1000 (10 x 100 ) kapslar (sjukhusförpackning); Blister, 500 (10 x 50 ) kapslar (sjukhusförpackning)
Godkänd
2009-11-13
PACAKAGE LEAFLET: INFORMATION FOR THE USER TREVILOR 37.5 MG PROLONGED-RELEASE CAPSULES, HARD TREVILOR 75 MG PROLONGED-RELEASE CAPSULES, HARD TREVILOR 150 MG PROLONGED-RELEASE CAPSULES, HARD venlafaxine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Trevilor is and what it is used for 2. What you need to know before you take Trevilor 3. How to take Trevilor 4. Possible side effects 5. How to store Trevilor 6. Contents of the pack and other information 1. WHAT TREVILOR IS AND WHAT IT IS USED FOR Trevilor contains the active substance venlafaxine. Trevilor is an antidepressant that belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions such as anxiety disorders. It is thought that people who are depressed and/or anxious have lower levels of serotonin and noradrenaline in the brain. It is not fully understood how antidepressants work, but they may help by increasing the levels of serotonin and noradrenaline in the brain. Trevilor is a treatment for adults with depression. It is also a treatment for adults with the following anxiety disorders: generalised anxiety disorder, social anxiety disorder (fear or avoidance of social situations) and panic disorder (panic attacks). Treating depression or anxiety disorders properly is important to help you get better. If it is not treated, your condition may not go away and may become more serious and more difficult to treat. 2. WHAT YOU N Läs hela dokumentet
Produktinformationen för Trevilor 37,5 mg, 75 mg, 150 mg depotkapsel, hård, MTnr 42825, 42826, 42827, gäller vid det tillfälle då läkemedlet godkändes. Informationen kommer inte att uppdateras eftersom läkemedlet inte marknadsförs i Sverige. Av samma anledning finns inte någon svensk produktinformation. Om läkemedelsnamnet i följande produktinformation inte stämmer med namnet på dokumentet, beror det på att läkemedlet i Sverige är godkänt under ett annat namn. 2/18 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Trevilor ® retard 37.5 mg Trevilor ® retard 75 mg Trevilor ® retard 150 mg Prolonged-release capsules, hard 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Venlafaxine _Trevilor retard 37.5 mg:_ One hard prolonged-release capsule contains 42.43 mg venlafaxine hydrochloride corresponding to 37.5 mg venlafaxine. _Trevilor retard 75 mg:_ One hard prolonged-release capsule contains 84.84 mg venlafaxine hydrochloride corresponding to 75 mg venlafaxine. _Trevilor retard 150 mg:_ One hard prolonged-release capsule contains 169.7 mg venlafaxine hydrochloride corresponding to 150 mg venlafaxine. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release capsules, hard 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. Treatment of panic disorder, with or without agoraphobia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Major depressive episodes 3/18 The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted due to symptom severity, dose increases can be made at more frequent intervals, but not less than 4 days. Because o Läs hela dokumentet